Effects of imipramine or GABA(B) receptor ligands on the immobility, swimming and climbing in the forced swim test in rats following discontinuation of cocaine self-administration.
We tested if discontinuation of cocaine self-administration can lead to the development of depressive-like symptoms in the forced swim test expressed as changes in immobility, swimming and climbing behaviors in rats. A "yoked" procedure in which rats were run simultaneously in groups of three, with two rats received the passive injection of cocaine or saline, was employed. Later, we examined whether acute treatment with the classical antidepressant imipramine or GABA(B) receptor ligands could alter the increases in immobility recorded after discontinuation of self-administered cocaine. We found a significant increase (44%) in the immobility time 3 days following discontinuation of cocaine (0.5mg/kg/infusion/2h daily) self-administration for 14 days; such enhancement resembled that observed in rats following the chronic mild stress. Acute administration with imipramine (15 or 30 mg/kg), the GABA(B) receptor agonists baclofen (0.125 mg/kg) and SKF 97541 (0.005 mg/kg), the positive allosteric modulator CGP 7930 (0.3mg/kg) or the antagonist SCH 50911 (0.3mg/kg) counteracted the cocaine discontinuation-induced enhancement in the immobility time. The enhanced immobility time in rats that self-administered cocaine (but not given cocaine passively) may reflect the motivated or cognitive processes of reinforced responding of cocaine and could be a potential driver of the addiction process per se. Moreover, either blockade or stimulation of GABA(B) receptors by their ligands in very low doses attenuated the enhanced immobility time in rats after discontinuation of cocaine self-administration and these findings extend preclinical studies demonstrating the potential involvement of GABA(B) receptor ligands to reduce cocaine craving.
Frankowska
Małgorzata
M
Laboratory of Drug Addiction Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland.
Gołda
Anna
A
Wydra
Karolina
K
Gruca
Piotr
P
Papp
Mariusz
M
Filip
Małgorzata
M
D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D003042:Cocaine / Q000008:administration & dosage* / Q000494:pharmacology; D003866:Depressive Disorder / Q000209:etiology / Q000503:physiopathology; D058786:GABA-B Receptor Agonists; D058788:GABA-B Receptor Antagonists; D007099:Imipramine / Q000008:administration & dosage / Q000494:pharmacology*; D007267:Injections; D008024:Ligands; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D009042:Motivation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D018080:Receptors, GABA-B / Q000378:metabolism*; D012646:Self Administration; D012965:Sodium Chloride / Q000008:administration & dosage; D013312:Stress, Physiological / Q000187:drug effects; D013550:Swimming; D013997:Time Factors
D000928:Antidepressive Agents; D058786:GABA-B Receptor Agonists; D058788:GABA-B Receptor Antagonists; D008024:Ligands; D018080:Receptors, GABA-B; D012965:Sodium Chloride; D003042:Cocaine; D007099:Imipramine